"Agilent Labs’ expertise in molecular
and computational biology is very important to our interdisciplinary
Reynolds Center," said Thomas Quertermous, M.D. (center),
William G. Irwin Professor and Chief of Stanford’s Division of Cardiovascular
Medicine. "We share the goal of understanding the basic mechanisms of heart
disease - a leading cause of death - in order to improve its prevention, diagnosis
pictured are Laurakay Bruhn, Ph.D. (left), Project Manager, Molecular Diagnostics
Department, Agilent Labs; and David Deng, Ph.D. (right), Research Scientist,
Molecular Diagnostics Department, Agilent Labs.
Collaborations between Agilent Laboratories and
leading research centers - such
as the Donald W. Reynolds Cardiovascular Clinical Research Center
at Stanford University - keep the Labs at the forefront of research
and provide an in-depth understanding of emerging trends. The Reynolds
Center and Agilent Labs are exploring use of Agilent’s microarrays
in new biomedical research applications that may lead to future diagnostic
Along with Agilent’s DNA microarrays and microarray systems, Agilent Labs is supplying proprietary computational tools and expertise in cardiovascular disease and information science. Using the Labs’ tools, the Reynolds Center can rapidly interpret data produced by tens of thousands of genes simultaneously as they interact to produce heart disease. Agilent’s ability to provide arrays with customized genetic content is critical in a research environment where the goal is to discover new genes of significance rather than to screen for known ones.
collaborating with Agilent Labs, we have access to molecular
biologists who help us optimize Agilent’s microarrays for
our work, and the world-leading
computational biologists at Labs are enabling us to guide
the development of the tools needed to meet our research
needs.” said Dr Quertermous.